An Open Label, Single Arm Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of HL2351 in Patients With Cryopyrin Associated Periodic Syndromes
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs HL 2351 (Primary)
- Indications Cryopyrin-associated periodic syndromes
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Handok Inc
- 03 Jan 2017 Status changed from recruiting to discontinued due to difficulties in recruiting.
- 04 Aug 2016 New trial record